Physician profile
Alberto Lopez
NPI 1356364244
$10,514.61
in general payments reported to CMS, 2019-2025
34 companies · $551 in 2025
The $551 reported for 2025 was more than what 80% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,426 · 2020: $486 · 2021: $920 · 2022: $2,033 · 2023: $1,304 · 2024: $794 · 2025: $551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,649.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,649.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $2,000.00 | 2019 | |
| Abbott Laboratories | $1,845.11 | 2019-2025 | Xience Skypoint, Cardiomems, Aveir |
| Janssen Pharmaceuticals, INC | $1,196.34 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $703.24 | 2022-2025 | Leqvio |
| Pfizer INC. | $537.35 | 2019-2025 | |
| Novo Nordisk INC | $464.82 | 2022-2025 | Ozempic, Wegovy, Fiasp |
| Kowa Pharmaceuticals America, INC. | $370.35 | 2019-2023 | Livalo |
| Boston Scientific Corporation | $355.01 | 2022-2023 | Watchman Access System, Watchman Flx |
| Actelion Pharmaceuticals US, INC. | $343.53 | 2019-2025 | Opsumit, Uptravi |
| Amgen INC. | $329.49 | 2019-2025 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $304.24 | 2022-2025 | Eliquis, Camzyos |
| Impulse Dynamics (USA) INC. | $214.81 | 2021-2023 | Optimizer |
| Sanofi-Aventis U.S. LLC | $202.54 | 2019-2023 | |
| Astellas Pharma US INC | $177.23 | 2019-2020 | |
| Irhythm Technologies, INC. | $174.89 | 2022-2024 | Zio Xt Patch, Zio Monitor |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $173.98 | 2020-2022 | |
| Cardiva Medical, INC. | $137.00 | 2022-2023 | Cardiva Vascade 6/7f Vcs |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.12 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $126.98 | 2021-2023 | Verquvo |
| Amarin Pharma, INC. | $120.93 | 2022-2023 | |
| Medtronic, INC. | $96.63 | 2021-2024 | Endurant Iis |
| Lexicon Pharmaceuticals, INC. | $83.85 | 2023-2024 | Inpefa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $81.39 | 2024-2025 | Lifevest |
| Biotronik INC. | $64.70 | 2021 | |
| Akcea Therapeutics, INC. | $57.86 | 2019-2020 | |
| Endologix LLC | $47.44 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $44.14 | 2022-2025 | |
| Vifor Pharma, INC. | $31.28 | 2021 | |
| Lilly USA, LLC | $23.46 | 2025 | Zepbound |
| Bracco Diagnostics INC. | $17.33 | 2022 | |
| Baxter Healthcare | $17.26 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Astrazeneca Pharmaceuticals LP | $16.01 | 2025 | Wainua |
| Heartflow, INC. | $13.52 | 2024 | |
| Medicure Pharma INC. | $11.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alberto Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.